» Download Article

Authors
dos Santos Ferreira, Jorge; Middleton, Rick

Identifier
10.3182/20090812-3-DK-2006.00059

Index Terms
Decision support and control of biomedical systems; Disease control and critical care,

Abstract
A mathematical model is developed to further examine the dynamic interaction of uninfected T cells with Human Immunodeficiency Virus (HIV) mutations. We study how the dynamics are affected by immune response to infected cells under intermittent antiretroviral therapy. Our goal is to analyze the SMART (Strategies for Management of Anti-retroviral Therapy) study outcomes and based on that try to identify possible causes of its failure. We mathematically describe the HIV infection and perform numerical simulation to approach the course of the disease. Preliminary results suggest that the scheduling of follow-up visits and working range of CD4+ T cells count used during the SMART study could explain the observed adverse outcomes in that trial.

References

Ananworanich, J., Gayet, A., Braz, M., Prasithsirikul,W., Chetchotisakd, P., Kiertiburanakuland, S., Raksakulkarn, W.M.P., Tansuphasawasdikul, S., Sirivichayakul, S., Cavassini, M., Karrer, U., Genné, D., Nüesch, R., Vernazza, P., Bernasconi, E., Leduc, D., Satchell, C., Yerly, S., L, L.P., Hill, A., Perneger, T., Phanuphak, P., Furrer, H., Ruxrungtham, D.C.K., Hirschel, B., Study, S., and Study, S.H.C. (2003). On
attaining maximal and durable suppression of the viral load. Lancet, 368, 459-465.

Annah, M. (2006). A control theoretical approach to hiv/aids. drug dosage design and timing the initiation of therapy. phd thesis, electrical, electronic and computer engineering-university of pretoria. 

Annah, M., Xiaohua, X., and Ian, K. (2007). Structured treatment interruptions: A control mathematical approach to protocol design. J. of Process Control, 17, 586-590. 

Autran, B. and Garcelain, G. (2000). Boosting immunity to hiv-can the virus help? Science, 290, 946-949. 

Bennett, S. (1993). A History of Control Engineering 1930-1955. Peter Peregrinus. 

Bethesda, M. (2006). Smart protocol. URL http://www.smart-trial.org. Nat. Instit. of Health.

Brian, B. (1998). The 16th aids conference: What did it achieve? Toronto, Canada.

Burman, W. (2006). The effect of episodic cd4-guided antiretroviral therapy on quality of life: results of the quality of life substudy of smart. XVI AIDS Conference, Toronto-Canada.

Cardiello, P., Hassink, E., Anaworanich, J., Srasuebkul, P., Samor, T., Mahanontharit, A., Ruxrungtham, K., Hirschel, B., Lange, J., Phanuphak, P., and Cooper, D. (2005). A prospective, randomized trial of structured treatment interruption for patients with chronic hiv type 1 infection. Clin Infect Dis, 40, 594-600.

Chun, T., Stuyver, L., Mizell, S., Ehler, L., Mican, J., Baseler, M., Lloyd, A., Nowak, M., and Fauci, A. (1997). Presence of an inducible hiv-1 latent reservoir during highly active antiretroviral therapy. PNAS, 94, 13193-13197.

Cohn, D. (2006). Severity and types of clinical events by proximal cd4 cell counts in the smart study. XVI AIDS Conference, Toronto-Canada.

Danel, C., Moh, R., Minga, A., Anzian, A., Gomis, O., Kanga, C., Nzunetu, G., gabillard, D., Ronet, F., Sorho, S., Chaix, M., Eholie, S., Menan, H., Sauvageot, D.,
Bissagnene, E., Salomon, R., Anglaret, X., and trial group, T.A. (2006). Cd4-guided structured antiretroviral treatment interruption strategy in hiv-infected adults in west africa (trivacan anrs 1269 trial): a randomized trial. Lancet, 367, 1981-1989.

Doherty, P. (1993). Immune exhaustion: driving virus specific cd8 t cells to death. Trends Microbiol., 213, 207-209.

El-Sadr, W. (2006). Inferior clinical outcomes with episodic cd4-guided antiretroviral therapy aimed at drug conservation in smart study: consistency of finding in all patient groups. 13th CROI, Denver-USA. Ferreira, J. and Middleton, R. (2008). A preliminary analysis of hiv infection. 6th IET Irish Signals and Systems Conference.

Ferreira, J., O’Donoghue, Y., and Middleton, R. (2009). Analysis of hiv mutation dynamics for a linear mutation tree. Submitted to American Control Conference,
Missouri-USA.

Jeffrey, A., Xia, X., and Craig, I. (2003). On attaining maximal and durable suppression of the viral load. 1st African Control Conference. Cape Town, South Africa.

Jeffrey, A. and Xia, X. (2002). Estimating the viral load response time after hiv  chemotherapy. 6th IEEE AFRICON, 1, 77-80.

Kalams, S., Philip, J., Shea, K., Norman, G., Trocha, A., Graham, S., and Walker, B. (1999). Levels of human immunodeficiency virus type 1-specific cytotoxic tlymphocyte
effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J. of Virology, 73, 6721-6728.

Kwon, H. (2007). Optimal treatment strategies derived from a hiv model with drug-resistant mutants. Appl. Math. Comput., 188, 1193-1204.

Lundgren, J. (2006). Progression of hiv-related disease or death (pod) in the randomized smart study: why was the risk of pod greater in the cd4-guided (re)-initiate art at cd4 < 250 cells/mcl) drug conservation (dc) vs the virological suppression (vs) arm? 13th CROI, Denver-USA.

Maggiolo, F., Ripamonti, D., and Gregis, G. (2003). Individualized structured treatment interruptions: results of a randomized, controlled study (basta). 43rd Annual ICAAC Chicago, USA.

Nowak, M. and Charles, R. (1996). Population dynamics of immune responses to persistent viruses. Science, 272, 74-79.

Palmer, S., Maldarelli, F., Wiegand, A., Bernstein, B., Hanna, G., Brun, S., Kempf, D., Mellors, J., Coffin, J., and King, M. (2008). Low-level viremia persists for at
least 7 years in patients on suppressive antiretroviral therapy. PNAS, 105, 3879-3884.

Panel, C. (2006). Panel on clinical practices for treatment of hiv infection. guidelines for the use of antiretroviralagents in hiv-infected adults and adolescents. XVI AIDS
Conference. August 13-18, Toronto, Canada, 47, 43-82.

Phair, J., Mellors, J., Detels, R.,Margolick, J., and Muñoz, A. (2002). Regulation of hiv-1 latency by t-cell activation. AIDS, 16, 2455-2459.

Richard, H. (2008). Virology, chap. 7, part 3. univ. of south carolina, school of med. URL http://pathmicro.med.sc.edu/lecture/HIV3.htm. Microbiology and Immunology On-line.

Rosenberg, E., Altfeld, M., Poon, S., Phillips, N., Wilkes, B., Eldridge, R., Robbins, G., Aquila, R., Goulder, P., and Walker, B. (2000). Immune control of hiv-1 after
early treatment of acute infection. Nature, 407, 523-526.

Sadr, W. and Neaton, J. (2006). Episodic cd4-guided use of art is inferior to continuous therapy: Results of the smart study. 13th CROI, Denver-USA.

SMARTgroup, M. (2006). Cd4 count-guided interruption of antiretroviral treatment. the strategies for management of antiretroviral therapy (smart) study group. NEJM, 355, 2283-2296.

Wodarz, D. (2001). Helper-dependent vs. helperindependent ctl responses in hiv infection-implications for drug therapy and resistance. J. theor. Biol, 213, 447-459.